<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04700007</url>
  </required_header>
  <id_info>
    <org_study_id>N-20200084 2nd sub-project</org_study_id>
    <nct_id>NCT04700007</nct_id>
  </id_info>
  <brief_title>Evaluation of Peripheral Itch Mechanisms Following Injection of Morphine (Second Sub-Project)</brief_title>
  <official_title>Effect of Intradermal Morphine Application on Histaminergic and Non-histaminergic Itch and Related TRPV1 and Antihistamine Treatments (2nd Sub-project)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aalborg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aalborg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of our 2nd sub-project is to clarify if the capsaicin receptor TRPV1 is implicated in&#xD;
      the mechanism of morphine-induced mast cell degranulation. Moreover, we also aim to clarify&#xD;
      if the mechanism of opioid-induced itch relay on the histaminergic pathway by using the&#xD;
      antihistamine (diphenhydramine) to suppress the release of histamine from peripheral mast&#xD;
      cells.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measuring itch intensity by computerized Visual Analog Scale Scoring</measure>
    <time_frame>For 10 minutes</time_frame>
    <description>We will ask the subjects to rate the sensation of itch on a 100 mm VAS scale ranging from 0 to 100 where 0 indicates &quot;no itch&quot; and 100 indicates &quot;worst itch imaginable&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measuring pain intensity by computerized Visual Analog Scale Scoring</measure>
    <time_frame>For 10 minutes</time_frame>
    <description>We will ask the subjects to rate the sensation of pain on a 100 mm VAS scale ranging from 0 to 100 where 0 indicates &quot;no pain&quot; and 100 indicates &quot;worst pain imaginable&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Superficial blood perfusion measurement</measure>
    <time_frame>After 15 minutes</time_frame>
    <description>Superficial blood perfusion is measured by a Speckle contrast imager</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>While size</measure>
    <time_frame>After 15 minutes</time_frame>
    <description>While size will be assessed using a ruler</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Itch</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capsaicin</intervention_name>
    <description>A capsaicin patch will be applied on a 3x3 cm squared area on the volar forearm. The patch will be left in place for 24h after which it will be removed.</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine</intervention_name>
    <description>Diphenhydramin cream 1% (Restamine®) will be applied on a 3x3 cm squared predetermined area on the volar forearm for 24 hours.</description>
    <arm_group_label>Study group</arm_group_label>
    <other_name>Antihistamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine Chloride</intervention_name>
    <description>Morphine solution (0.1mg/ml, Morphine Hydrochloride) 50 μl will be applied intradermally to the center of a predetermined area on the volar forearm by a 1 ml syringe.</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotonic saline</intervention_name>
    <description>injections of isotonic saline (0.05 ml, 0.9%) as vehicle will be performed.</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Histamine</intervention_name>
    <description>A small drop of histamine dihydrochloride (1%, in saline) will be applied to a previously determined area on the volar forearm followed by a prick through the drop.</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy men and women&#xD;
&#xD;
          -  18-60 years&#xD;
&#xD;
          -  Speak and understand English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with any clinically significant abnormalities that in the opinion of the&#xD;
             investigator may increase the risk associated with trial participation or may&#xD;
             interfere with the interpretation of the trial results.&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Drug addiction defined as any use of cannabis, opioids or other addictive drugs&#xD;
&#xD;
          -  Lack of ability to cooperate&#xD;
&#xD;
          -  Current use of medications that may affect the trial such as antihistamines,&#xD;
             antipsychotics and pain killers as well as systemic or topical steroids.&#xD;
&#xD;
          -  Participants with known allergy/discomfort to the opioid morphine and antihistamine.&#xD;
&#xD;
          -  Skin diseases&#xD;
&#xD;
          -  Moles, scars or tattoos in the area to be treated or tested.&#xD;
&#xD;
          -  Consumption of alcohol or painkillers 24 hours before the study days and between these&#xD;
&#xD;
          -  Acute or chronic pain&#xD;
&#xD;
          -  Participation in other trials within 1 week of study entry (4 weeks in the case of&#xD;
             pharmaceutical trials)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mech-Sense, Medicinsk Gastroenterologisk ambulatorium, Medicineshus, Aalborn Universitethospitalet</name>
      <address>
        <city>AAlborg</city>
        <state>Nordjylland</state>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia L Lo Vecchio, Phd</last_name>
      <phone>21397785</phone>
      <email>slv@hst.aau.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 6, 2021</study_first_submitted>
  <study_first_submitted_qc>January 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2021</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aalborg University</investigator_affiliation>
    <investigator_full_name>Silvia Lo Vecchio</investigator_full_name>
    <investigator_title>PhD, Assistant Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Capsaicin</mesh_term>
    <mesh_term>Histamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

